• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Harold L. Paz on Aetna's Transition Towards Wellness and Value

Video

Aetna is in the process of transforming from a traditional health insurance company to becoming a healthcare-focused company, in part by emphasizing value-based reimbursement and social determinants of health, said Harold L. Paz, MD, MS, executive vice president and chief medical officer at Aetna.

Aetna is in the process of transforming from a traditional health insurance company to becoming a healthcare-focused company, in part by emphasizing value-based reimbursement and social determinants of health, said Harold L. Paz, MD, MS, executive vice president and chief medical officer at Aetna.

Transition (slightly modified)

What challenges do you foresee as Aetna continues to move toward value-based care?

For Aetna I would say the opportunity, and with that the challenge, is how we transform this company from being a traditional health insurance company to becoming a healthcare company. And that’s really our focus in our Vision 2020 strategic plan. We believe that in the future the emphasis will be on value-based reimbursement models and the need to really coordinate care for individuals that bring in the social determinants of health and the multiple determinants of health to increase the number of healthy days that each individual has. That’s not just physical health, but it’s mental health, and it’s social health.

To do that effectively, it really requires creating these innovative partnerships that begin in the home and are based in the community. That is a massive transformation for Aetna, but it is one that we’re fully committed to. It is in our vision and that’s what our entire strategic plan is predicated on.

Related Videos
Bhavana (Tina) Bhatnagar, DO, West Virginia University Cancer Institute at Wheeling Hospital
Dr Debra Patt
Dr Marco del Riccio
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Dr Yara Abdou
Michael David Chuong, MD, radiation oncologist, Miami Cancer Institute, Baptist Health South Florida
Yuman Fong, MD, cancer surgeon, City of Hope
Dr Marco del Riccio
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
© 2026 MJH Life Sciences
AJMC®
All rights reserved.